Ipca Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 524494 | NSE: IPCALAB | Pharmaceuticals & Drugs | Mid Cap

Ipca Laboratories Share Price

1,223.85 -0.05 0.00%
as on 12-Jul'24 16:01

DeciZen - make an informed investing decision on Ipca Laboratories

Overall Rating
Bole Toh

1. Quality

2. Valuation


3. Price Trend

Semi Strong

Ipca Laboratories stock performance -

mw4me loader
P/E Ratio (SA):
Market Cap:
31,028 Cr.
52-wk low:
52-wk high:

Is Ipca Laboratories Ltd an attractive stock to invest in?

1. Is Ipca Laboratories Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Ipca Laboratories Ltd is a good quality company.

2. Is Ipca Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Ipca Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Ipca Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Ipca Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Ipca Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Ipca Laboratories Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 22.9%9.3%4.3%6.1%7.6%13.8%17.3%24.7%15.6%8%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3,2353,0882,8043,1023,1933,6064,3385,1145,4055,7756,166
Sales YoY Gr.--4.5%-9.2%10.7%2.9%12.9%20.3%17.9%5.7%6.8%-
YoY Gr.--53.2%-54%54.1%30.2%102.9%41.7%69.7%-22.3%-41.3%-
BVPS (₹) 78.588.590.598.1106.8124.1145.1187.3215.8231.7250.2
Adj Net
Cash Flow from Ops. 5154556962713244965611,096832762-
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.7%12.6%10%6.8%
Adj EPS -0.4%17.4%-8.2%-41.3%
Share Price 11.2% 20.6% 4.8% 58%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 10.01%

Return on Equity has declined versus last 3 years average to 8.70%

Net Profit has been subdued in last 3 years -8.16%

Sales growth is not so good in last 4 quarters at 6.09%

Latest Financials - Ipca Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 20.9 21.6
TTM Sales (₹ Cr.) 6,166 7,705
BVPS (₹.) 250.2 249.6
Reserves (₹ Cr.) 6,323 6,307
P/BV 4.89 4.90
PE 58.50 56.69
From the Market
52 Week Low / High (₹) 761.30 / 1373.95
All Time Low / High (₹) 2.83 / 1383.55
Market Cap (₹ Cr.) 31,028
Equity (₹ Cr.) 25.4
Face Value (₹) 1
Industry PE 43.9

Management X-Ray of Ipca Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Ipca Laboratories

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 2,5282,5822,5462,7042,7662,9273,4393,6644,2204,887
Manufacturing Costs539571521549519538647703825903
Material Costs9549568919379661,0101,2921,4021,5631,843
Employee Cost 4785416036757137528719491,1021,193
Other Costs 558514531543568626630610730947
Operating Profit 7065052583994276798981,4501,185888
Operating Profit Margin (%) 21.8%16.4%9.2%12.9%13.4%18.8%20.7%28.4%21.9%15.4%
Other Income 51594657587284129109137
Interest 28293126272119111046
Depreciation 101177161171174172179188210229
Exceptional Items 0000000000
Profit Before Tax 6293581112582835577851,3801,074750
Tax 152102197050102133239214245
Profit After Tax 477256931882334556521,141860506
PAT Margin (%) 14.8%8.3%3.3%6.1%7.3%12.6%15.0%22.3%15.9%8.8%
Adjusted EPS (₹)18.910.
Dividend Payout Ratio (%)13%5%0%7%5%8%10%9%12%20%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 1,9822,2332,2832,4752,6953,1373,6664,7535,4765,877
Share Capital 25252525252525252525
Reserves 1,9562,2082,2582,4502,6693,1113,6404,7275,4505,852
Minority Interest0000000000
Long Term Debt292501484352234134789395652
Short Term Debt138321183177239196309147338627
Trade Payables337303415388415464538526492451
Others Liabilities 469466539576525527593574738840
Total Liabilities 3,2173,8243,9053,9684,1084,4585,1856,0107,4388,447

Fixed Assets

Gross Block1,8512,4662,1372,2772,3592,4132,6792,8883,3713,889
Accumulated Depreciation5457131613315046738381,0041,2021,410
Net Fixed Assets1,3061,7531,9771,9461,8551,7401,8411,8842,1692,479
CWIP 16526712995736684182297123
Investments 2982972122163226498681,3391,057
Trade Receivables449354441502594632839774824926
Cash Equivalents 69113162181312601523075961,706
Others Assets361339266322366382352477434496
Total Assets 3,2173,8243,9053,9684,1084,4585,1856,0107,4388,447

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity 5154556962713244965611,096832762
PBT 6293581112582835577851,3801,074750
Adjustment 134182201162185175181173221206
Changes in Working Capital -118-10412-95-87-129-258-215-27121
Tax Paid -130-74-29-54-57-108-146-242-192-215
Cash Flow From Investing Activity -362-686-214-146-119-123-499-560-814-710
Capex -370-554-240-133-71-66-260-347-448-401
Net Investments -3-144417-15-49-48-236-45
Others 12-11822-17-65-43-189-165-130-264
Cash Flow From Financing Activity -138255-414-156-130-223-139-307426506
Net Proceeds from Shares 00000503600
Net Proceeds from Borrowing -2719450-126-149-155-115-68347363
Interest Paid -28-31-28-23-22-17-14-6-5-39
Dividend Paid -66-37-150-15-15-122-102-101-101
Others -17129-421-856-40113-168185283
Net Cash Flow 142568-3174150-76229444559
ROE (%)26.8812.154.17.919.0215.619.1827.116.828.91
ROCE (%)27.5713.484.528.979.5316.7620.8430.5419.3411.77
Asset Turnover Ratio1.10.890.740.80.80.850.910.920.810.73
PAT to CFO Conversion(x)1.081.787.481.441.391.090.860.960.971.51
Working Capital Days
Receivable Days48475155626261575455
Inventory Days881031129999979799111108
Payable Days8910514114613714012612310483

Ipca Laboratories Ltd Stock News

Ipca Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Ipca Laboratories on 12-Jul-2024 16:01 is ₹1,223.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Jul-2024 16:01 the market cap of Ipca Laboratories stood at ₹31,028.
The latest P/E ratio of Ipca Laboratories as of 12-Jul-2024 16:01 is 58.50.
The latest P/B ratio of Ipca Laboratories as of 12-Jul-2024 16:01 is 4.89.
The 52-week high of Ipca Laboratories is ₹1,374 and the 52-week low is ₹761.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Ipca Laboratories is ₹6,166 ( Cr.) .

About Ipca Laboratories Ltd

Ipca Laboratories Limited incorporated in the year 1949, is integrated pharmaceutical company manufacturing and marketing various formulations and many API’s covering various therapeutic segments. The products of the company are sold in many countries across the globe. The company has numerous manufacturing units in India manufacturing API’s and formulations for the world market.

Ipca Laboratories is one of the largest suppliers of these APIs worldwide with manufacturing leadership in many APIs globally. It has various APIs and formulations manufacturing facility across the globe. The company has leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy in India.

Business area of the company

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations.

Services and products

  • API- Ipca produces various APIs at its production facilities. Its core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness in a dynamic market. Ipca has also emerged as one of India’s top exporters of APIs, serving in many countries around the globe.
  • Branded Formulations- The company is leaders in Pain, Rheumatology, Antimalarials and Haircare therapies with a steadily growing portfolio.



  • The company started marketing of sugarcoated Chloroquine tablets, first time in India.


  • Ipca launched formulations of Metoclopramide under brand name 'Perinorm' for the first time in India.
  • Launched 'Ipca Contact', company's in-house Magazine.


  • Ipca launched formulations of Bromhexine for the first time in India.


  •  R&D-API and R&D-Formulation development departments set up to provide technology based products.


  • First company after Eli Lilly to develop a pre-constituted formulation of Erythromycin Estolate (Eltocin Liquid).


  • First API plant commissioned at Ratlam
  • Ipca second Formulations manufacturing plant commissioned at Ratlam


  • Production of Pyrantel Pamoate API commenced for the first time in India
  • Ipca commenced manufacturing of Injectables at the Ratlam formulations unit.


  • Ipca first API Plant for manufacturing of Chloroquine Phosphate set up at Ratlam
  • Production of API Atenolol, for the first time in India, commenced at Ratlam.


  • Acquired Hoechst India's formulations unit at Kandla


  • Maiden Public Issue of shares
  • Ipca acquired API manufacturing plant from BDH Pharmaceuticals (a subsidiary of E-Merck) at Indore


  • Ipca commissioned modern formulations plant at Athal (Silvassa)


  • The company commissioned new API R&D Centre at Mumbai


  • Launched 3C (Comprehensive Cardiac Care) Domestic Marketing Division, dedicated to promote cardiac care products
  • Ipca - Athal, Formulations manufacturing unit received prestigious approval from UK-Medicines and Healthcare products Regulatory Agency (MHRA) formerly known as UK- Medicines Control Agency (MCA)
  • Ipca - Athal, Ipca - Kandla and Ipca - Ratlam Formulations manufacturing plants received the prestigious approval from MCC (Medicines Control Council) South Africa.


  • First to introduce formulation of Hydroxychloroquine Sulphate under brand name 'HCQS' in India


  • Received ISO 9001 certification for Ipca Athal formulations Plant


  • 'Trishul' the highest award was conferred on Ipca Laboratories Ltd. by CHEMEXIL (Basic Chemicals, Pharmaceuticals & Cosmetics Export Promotion Council) for outstanding export performance
  • Launched new domestic marketing division - Innova, to promote speciality products in therapeutic segments of Psychiatry, Neurology and Dermatology
  • Ipca acquired 'National Druggists (Pty) Ltd.' in South Africa
  • Ipca Pharma Nigeria Ltd.' incorporated in Nigeria.


  • Launched new domestic marketing division - Intima, to promote established brands with a focus on micro-interior marketing.
  • Wholly owned subsidiary 'Laboratories Ipca Do Brasil Ltd.' incorporated in Brazil.


  • Launched new domestic marketing division - Activa, dedicated to Rheumatology Care. First company in India to have such division for marketing super-speciality molecules.
  • Launched new domestic marketing division - Hycare, dedicated to Cardio-Diabetology segments.
  • Wholly owned subsidiary 'Ipca Pharmaceuticals Inc.' incorporated in United States of America.
  • Wholly owned subsidiary 'Ipca (UK) Ltd.' incorporated in United Kingdom.
  • Forbes, a leading US business magazine, selected Ipca among its top 200 successful, rising companies outside USA, with sales under $1 billion.


  • Commissioned new Formulations manufacturing plant at Silvassa.
  • Ipca Laboratories Ltd. received 'Lifetime Achievement Award' for the year 2002-03 from CHEMEXIL (Basic Chemicals, Pharmaceuticals & Cosmetics Export Promotion Council) for export promotion over the years.
  • CDRI licenses novel Antimalarial compound to Ipca Ipca - Ratlam, API manufacturing facility inspected by US-FDA and the facility was found to be in compliance with global GMP requirements. The plant and the facilities have been recommended for manufacturing Atenolol, Propranolol Hydrochloride, Hydroxychloroquine Sulphate and Chloroquine Phosphate Forbes Asia, a leading US business magazine selected Ipca, for the second consecutive year as one among the first 200 'Best under a Billion Company' in Asia.


  • Merger of Innotech Pharma Limited with Ipca in August, 2005.
  • Ipca acquires cardiac brand Isordil from Wyeth Limited.
  • Forbes Asia, a leading US business magazine selected Ipca, for the third consecutive year, as one among the first 200 'Best under a Billion Company' in Asia.


  • Ipca launches Fixed dose ACT combination for treatment of malaria and stops manufacturing of single ingredient Oral Artemisinin derivatives.
  • Ipca enters into strategic alliance with Ranbaxy Pharmaceuticals Inc. for the U.S market.
  • Ipca new formulations plant at Dehradun commenced operation on May 05.


  • January - Ipca - Ranbaxy Alliance receive U.S. FDA marketing approval for Atenolol Tablets.
  • March - Ipca launched eighth domestic marketing division - Altus which caters to intensivists and surgeons. New Biotech Research & Development Unit was inaugurated at Mumbai.
  • June - Ipca - Ranbaxy Alliance receive U.S. FDA marketing approval for Hydroxychloroquine Sulfate (HCQS) Tablets.
  • July - Ipca - Ranbaxy Alliance receive U.S. FDA marketing approval for Hydrochlorothiazide (HCTZ) Tablets.
  • August - Ipca - Ranbaxy Alliance receive U.S. FDA marketing approval for Metformin HCl Tablets.
  • September - Acquisition of 100% shareholding of Formulation Dossier registration holding companies in Australia and New Zealand. The Australian company is currently holding five formulation registration dossiers in that country.
  • October - Ipca Laboratories Ltd. has been awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2007. In the past, company has received same award for three consecutive years' 2003, 2004 and 2005.
  • December - Ipca - Ratlam received 2nd prize in the 'National Energy Conservation Award-2007' in Drug and Pharmaceuticals sector from the Bureau of Energy efficiency under the Ministry of Power, Government of India, New Delhi.


  • January - 'Ipca Who' Brochure wins ABCI Gold Award, (Association of Business Communicators of India) 48th annual Awards for Excellence in Creative Business Communications.
  • Altus division launches Gardcef, a novel combination of Ceftazidime plus Sulbactam.
  • February - Tonira Pharma's Nandesari unit (API plant at Baroda) receive US-FDA approval.
  • March - Ipca - Piparia, Formulations manufacturing unit receive MHRA-UK approval. This is the 3rd plant after Athal and Kandla receiving this approval.
  • April - WHO prequalify Ipca dossier of Artesunate plus Amodiaquine co-blister making Ipca the 2nd company in the world and the 1st Indian company to receive this pre-qualification.
  • Ipca - Piparia, Formulations manufacturing unit receive US-FDA approval. Ipca - Ratlam, API manufacturing unit receive US-FDA re-approval.
  • May - WHO Geneva re-approved Ipca - Ratlam, API manufacturing unit for the third time.
  • Ipca Laboratories Ltd. has been awarded third position in, case-study presentation during the '10th National Suggestion Summit' organized by INSSAN-Northern Indian Chapter (NIC), New Delhi.
  • Ipca - Ratlam, API manufacturing unit got approval from Pharmaceutical and Medical Devices Agency (PMDA), Japan
  • Ipca completes management acquisition of Tonira Pharma Ltd. through public offer.
  • Ipca - Ratlam, Formulations manufacturing unit receive approval from Colombia Invima.
  • June - Ipca became the first company to launch formulation brand HCQS (Hydroxy Chloroquine Sulphate) in Kenya after innovator brand.
  • June - Ipca Laboratories Ltd., bags D&B - ECGC Indian Exporters Excellence Award - Topmost Exporter of Pharmaceutical Large Sector. Ipca receives approval from US FDA to manufacture Propranolol Hydrochloride Tablets.
  • July - Clinton Foundation announces New Agreements on Supply of anti-malarial Drugs, inter-alia, with Ipca.
  • August - Dr. Paul Bacon, Professor Emeritus, University of Birmingham, UK, a world renowned authority in Rheumatoid arthritis addressed leading clinicians in six metro towns in India.
  • November -'Ipca Contact' wins Silver medal in ABCI's (Association of Business Communicators of India) 48th annual Awards for Excellence in Creative Business Communications.
  • December - Ipca Laboratories Ltd. - Hycare division wins 'The Best Participation Award' at the conference of CSI (Cardiological Society of India) 2008.
  • December - Tonira Pharma's API manufacturing plants situated at Ankleshwar and Nandesari receive PMDA-Japan approval.


  • January - Study entitled 'Comparative Evaluation of Efficacy and Safety of Cefotaxime-Sulbactam with Amoxicillin-Clavulanic Acid in Children with lower respiratory tract infections' conducted by Clinical Research Department accepted for poster symposium by 2nd Congress of the European Academy of Pediatrics, held at Nice, France.
  • The first preclinical study conducted by Clinical Research Department entitled 'In Vivo Antimalarial Activity of Oral Beta-Arteether and Piperaquine Combination' published in Italian Journal 'Pharmacology Online'.
  • Clinical trial conducted by Clinical Research Department of Ipca entitled 'Comparative Evaluation of Efficacy and Safety of Cefotaxime-Sulbactam with Amoxicillin-Clavulanic.
  • Acid in Children with lower respiratory tract infections' published in 'Expert Opinion on Pharmacotherapy'.
  • Ipca's Green Technology Department published first research paper on 'Optimization of extract conditions and HPTLC-UV method of determination of quinine in different extracts of Cinchona spp. bark' in an international peer-reviewed Journal 'Records of Natural Products'. Green Technology Department is working on production of phytopharmaceuticals like, Artemisinin and Quinine sulphate. This department is also involved in contract farming of Artemisia annua.
  • European patent office has issued patent rights to Ipca for its method of making Carvedilol with patent number EP1741700.
  • United States patent office has issued patent rights to Ipca for its method of making Tramadol with patent number US7470816.
  • March - European Patent office has issued patent rights to Ipca for its method of making Alendronic acid with patent number EP1803727.
  • April - Clinical trial entitled 'A randomized, multicentric, comparative evaluation of aceclofenac-paracetamol combination with aceclofenac alone in Indian patients with osteoarthritis flare-up' has been published in 'Expert Opinion on Pharmacotherapy' journal in UK.
  • July - A randomized, comparative, multicentric evaluation of atenolol/amlodipine combination with atenolol alone in essential hypertensive patients was published in 'American Journal of Therapeutics' Philadelphia.
  • Aceclofenac-tizanidine in the treatment of acute low back pain: a doubleblind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone was published in 'European Spine Journal', Switzerland.
  • A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with Losartan hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension was published in 'Expert Opinion on Pharmacotherapy' UK.
  • United States patent office has issued patent rights to Ipca for its method of making Ondansetron with patent number US7547791.
  • September - WHO/MMV organized 4th Antimalarial conference first time in India with Ipca as the primary partner.
  • October - Ipca Laboratories Ltd. received Pharmexcil 'Gold Patent award' for the year 2008-2009. Ipca Laboratories Ltd. bagged this award in recognition of commendable contribution in the field of API. Pharmexcil is setup by Ministry of Commerce and Industry, Govt. of India.
  • Clinical study entitled 'Antihypertensive Efficacy of Metoprolol XL/Low Dose Chlorthalidone Combination: A Randomized, Comparative study in Indian patients with mild-to-moderate Essential Hypertension' published in European Journal of Medical Research.
  • November - Ipca - Ratlam celebrates Silver Jubilee of its existence.
  • December - United States patent office has issued patent rights to Ipca for its method of making Methylphenidate with patent number US7459467.
  • IDMA's Quality Excellence Award 2009 - Silver Medal honored to Ipca - Dehradun plant.
  • Ipca - Dehradun formulations plant, received award for 'Energy Conservation' from Uttrakhand Renewable Energy Development Agency (UREDA) on the occasion of National Energy Conservation Day.


  • January - Clinical study entitled 'Efficacy and Tolerability of a Fixed-Dose Combination of Metoprolol Extended Release/Amlodipine in Patients with mild-to-moderate Hypertension' published in Clinical Drug Investigation; an Adis publication.
  • The 'Clinical Drug Investigation' is an international peer-reviewed journal publishing original findings of the world's leading drug research.
  • February - New CRAMS division - Covenance, launched, which caters to the outsourcing needs of the pharma companies
  • March - New domestic Division, 'Ipca Nephrosciences' launched, which caters to Nephrologists and deals with kidney transplant and dialysis patients.
  • Ipca launches another domestic cardio-diabetic marketing division '3D'.
  • June - Ipca Laboratories Ltd., among the 100 Best Companies to work in India. The survey was conducted throughout India jointly by The Great Place to Work® Institute, India and The Economic Times across various organizations as a part of the 'India's Best Companies to Work For- 2010'. Study results were published in The Economic Times dated 20th June, 2010.
  • Clinical study entitled 'Efficacy and safety of Aceclofenac and Drotaverine fixed-dose combination in the treatment of primary dysmenorrhoea: a double-blind, double-dummy, randomized, comparative study with Aceclofenac' is published in European Journal of Obstetrics & Gynaecology and Reproductive Biology. It is the leading clinical journal which provides a forum for scientific and clinical professional communication in obstetrics and gynaecology throughout the world.
  • Clinical study entitled 'Evaluation of Efficincy and Tolarability of Gliclazide and Metformin Combination : A Multicentric Study in Patients with Type-2 Diabetes Mellitus, Uncontrolled on Monotherapy with Sulfonylurea or Metformin' is published in American Journal of Therapeutics.
  • July - Ipca - Aurangabad API manufacturing plant assessed by AFAQ-EAQA as complies with the Occupational Health & Safety Management System requirements of OHSAS 18001:2007.
  • AFNOR (Certification) certifies that the management system implemented by Ipca - Aurangabad, API manufacturing plant for manufacturing and supply of Bulk Drugs (Active Pharmaceutical Ingredients) has been assessed and found to meet the requirements of ISO 14001:2004.
  • Seventh Clinical Trial in Pain Management published in 'The Clinical Journal of Pain - official journal of eastern pain association' The Clinical Journal of Pain is a peer-reviewed journal that explores all aspects of pain and its effective treatment, bringing readers the insights of leading anaesthesiologists, surgeons, internists, neurologists, orthopaedists, psychiatrists and psychologists, clinical pharmacologists and rehabilitation medicine specialists.
  • August - United States Patent office has issued patent rights to Ipca for its novel process for manufacturing of API Isotretinoin. This is the Nineth patent granted by United States Patent office on API to Ipca.
  • September - Ipca Laboratories Ltd. received Pharmexcil Gold Patent award for the year 2009-2010, for the second consecutive year. This award was in recognition of commendable contribution in the field of API. The award was given for overall group of granted patents in API category during the year 2009-10.
  • Mint newspaper published 500 Best Performing midsize firms compiled by Inc. magazine and Ipca ranks at 51st position.
  • October - Ipca joins hands with BMC (Brihanmumbai Municipal Corporation) to fight against Malaria. BMC decided to release a film on 'Malaria & its Prevention'. Ipca was called to partner with them due to its long standing credibility and expertise in this field.
  • November - 'Ipca Contact', in-house quarterly magazine wins 'Bronze' medal in Headline Category in ABCI 50th Awards Nite.
  • December - Ipca - Ratlam formulations plant ranked third position in the National Energy Conservation Award 2010.
  • Ipca - Dehradun formulation plant at Dehradun receives 'Uttarakhand Energy Conservation Award 2010'. Ipca - Dehradun plant stood first in entire State of Uttarakhand.


  • Launched, Laxtaz the new age laxative that combines Ispaghula with Lactitol.
  • Launched CTD (Chlorthalidone), a novel antihypertensive which has the longest half life and is more effective than Amlodipine and Lisinopril.
  • Launched new division Ipca-Dynamix, which will cater to cardiovascular, gastrointestinal, antibacterial, respiratory segments.
  • Launched Rapiclav 1g in West African countries of Ivory Coast, Mali, Senegal, Burkina Faso, Benin & Nigeria.


  • Ipca received 'Corporate Citizen Award' for best corporate governance practice.


  • IPCA Laboratories gets OAI status from USFDA for Piparia unit.
  • Ipca Laboratories has entered into an agreement with a leading product development partnership, Medicines for Malaria Venture (MMV), to co-develop a novel antimalarial co-formulation named ‘Atoguanil’.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.